105
Arginase-2 (Arg2) Inhibitor
Cancer Research Horizons
Antibody
Oncology
Hit To Lead or Lead Optimization
• An ARG2-specific inhibitory monoclonal antibody would restore antitumour immunity in cancer patients and improve overall survival.
• Developed first-in-class inhibitory antibodies that potently and selectively inhibit arginase 2 (Arg2), using phage display technology.
• Antibodies are fully human with favorable pharmacokinetics. Published May 2020 in PNAS (https://doi.org/10.1073/pnas.1919565117).
• Lead molecule C0021061 has been assessed in vivo and chosen for further development (https://doi.org/10.1080/19420862.2020.1801230).
• Potential indications include oncology, COPD, cystic fibrosis and atherosclerosis.
WO2021032891A1
• Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation. PNAS, (2020)
• Structural and functional characterization of C0021158, a high-affinity monoclonal antibody that inhibits Arginase 2 function via a novel non-competitive mechanism of action. mAbs, (2020)
